Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Press Releases
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société MAYNE PHARMA GROUP LIMITED
03:32aMAYNE PHARMA : Notification regarding unquoted securities - MYX
PU
09/22MAYNE PHARMA : Fda approves lexetteo for adolescent plaque psoriasis
AQ
09/21MAYNE PHARMA : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
09/02MAYNE PHARMA : Change of Director's Interest Notice
PU
08/27MAYNE PHARMA : 2021 Full Year Media Release
PU
08/27MAYNE PHARMA : 2021 Full Year Investor Presentation
PU
08/27MAYNE PHARMA : Appendix 4E and Statutory Accounts
PU
08/26MAYNE PHARMA : 27/08/2021 Mayne Pharma 2021 Full Year Results Media Release
PU
08/26MAYNE PHARMA : board renewal and new Chairman
PU
08/03MAYNE PHARMA : Class action proceeding
AQ
08/03MAYNE PHARMA : 03/08/2021 MYX - Class action proceeding
PU
08/03MAYNE PHARMA : Notification of cessation of securities - MYX
PU
08/02MAYNE PHARMA : Change of Director's Interest Notice
PU
06/22Estelle Oral Contraceptive Now Available In the United States
AQ
06/20MAYNE PHARMA : 21/06/2021 Nextstellis® Oral Contraceptive Now Available in the United Stat..
PU
06/20MAYNE PHARMA : 21/06/2021 Mayne Pharma Expands Australian Dermatology Portfolio
PU
05/28Mayne - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Published
AQ
05/27MAYNE PHARMA : Nextstellis receives fda marketing exclusivity and phase iii data published
AQ
05/26MAYNE PHARMA : 27/05/2021 Nextstellis® Receives FDA Marketing Exclusivity and Phase III Da..
PU
05/13MAYNE PHARMA : Appendix 2A and Notice under ASX Listing Rule 3.10A
PU
04/16MAYNE PHARMA : 16/04/2021 u.s. fda approves nextstellis®, new oral contraceptive
PU
04/16MAYNE PHARMA : And mithra announce fda approval of new oral contraceptive nextstellis
AQ
04/16Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle
AQ
04/15MAYNE PHARMA : 16/04/2021 FDA approval of novel oral contraceptive NEXTSTELLIS
PU
03/08MAYNE PHARMA : 08/03/2021 New data on NEXTSTELLIS presented at ISSWSH conference
PU
02/25MAYNE PHARMA : 2021 Half Year Results Media Release
AQ
02/23MAYNE PHARMA : 24/02/2021 Mayne Pharma 2021 Half Year Results Media Release
PU
01/06MAYNE PHARMA : launches Microgestin 24 FE tablets in the US
PU
01/06MAYNE PHARMA : 07/01/2021 Mayne Pharma launches Microgestin® 24 Fe tablets in the United S..
PU
2020MAYNE PHARMA : 18/12/2020 Mayne Pharma successfully extends debt facility
PU
2020MAYNE PHARMA : successfully extends debt facility
PU
2020MAYNE PHARMA : 24/11/2020 2020 AGM Chairman's Address
PU
2020MAYNE PHARMA : 24/11/2020 2020 AGM CEO's Speech
PU
2020MAYNE PHARMA : 09/11/2020 Mayne Pharma Board Renewal
PU
2020MAYNE PHARMA : Board Renewal
PU
2020MAYNE PHARMA : New data on Mayne Pharma's TOLSURA presented at IDWeek 2020
AQ
2020MAYNE PHARMA : 26/10/2020 New data on Mayne Pharma's TOLSURA presented at IDWeek 2020
PU
2020MAYNE PHARMA : Lapse of rights and AGM Notice of Meeting clarification
PU
2020MAYNE PHARMA : 2020 Annual General Meeting
PU
2020MAYNE PHARMA : 2020 Corporate Governance Statement
PU
2020MAYNE PHARMA : Annual Report to shareholders
PU
2020Mithra Announces FDA update
AQ
2020MAYNE PHARMA : provides update on Women's Health pipeline
AQ
2020MAYNE PHARMA : 06/10/2020 Mayne Pharma provides update on Women's Health pipeline
PU
2020MAYNE PHARMA : Appoints Chief Financial Officer
AQ
2020MAYNE PHARMA : appoints new CFO
PU
2020MAYNE PHARMA : 29/09/2020 Mayne Pharma Appoints Chief Financial Officer
PU
2020MAYNE PHARMA : Appendix 4E and Statutory Accounts
PU
2020MAYNE PHARMA : 2020 Full Year Media Release
PU
2020MAYNE PHARMA : 2020 Full Year Investor Presentation
PU
2020MAYNE PHARMA : 21/08/2020 Mayne Pharma FY20 Results Media Release
PU
2020MAYNE PHARMA : Announces strategic partnership with novast
AQ
2020MAYNE PHARMA : Announces Expansion of US Production Space
AQ
2020Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle in the US
AQ
2020MAYNE PHARMA : Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the ..
AQ
2020MAYNE PHARMA : Toni Nesci named head of Mayne Contract Services and New Website Launched
AQ
2020MAYNE PHARMA : signs license agreement for contraceptive in Australia
AQ
2020MAYNE PHARMA : submits NDA for E4/DRSP to the FDA
AQ
2020MAYNE PHARMA : Resignation of group chief financial officer and appointment of interim cfo..
AQ
2020MAYNE PHARMA : 20/03/2020 Change of CFO and Company Secretary
PU
2020MAYNE PHARMA : 2020 Half Year Media Release
PU
2020MAYNE PHARMA : Half Yearly Report and Accounts
PU
2020MAYNE PHARMA : 2020 Half Year Investor Presentation
PU
2020MAYNE PHARMA : 21/02/2020 Mayne Pharma 2020 Half Year Media Release
PU
2019MAYNE PHARMA : Aspires To Specialisation
AQ
2019MAYNE PHARMA : Final Director's Interest Notice
PU
2019MAYNE PHARMA : 22/11/2019 2019 AGM CEO's Speech
PU
2019MAYNE PHARMA : 22/11/2019 2019 AGM Chairman's Address
PU
2019MAYNE PHARMA : 2019 AGM CEO's Speech
PU
2019MAYNE PHARMA : 2019 AGM Chairman's Address
PU
2019MAYNE PHARMA : 23/10/2019 E4/DRSP contraceptive presented at EU gynecology conference
PU
2019MAYNE PHARMA : E4/DRSP contraceptive presented at EU gynecology conference
PU
2019MAYNE PHARMA : Retirement of Director
PU
2019MAYNE PHARMA : 21/10/2019 Retirement of Director
PU
2019MAYNE PHARMA : 21/10/2019 Notice of Annual General Meeting/Proxy Form
PU
1  2  3  4Next
Upcoming event on MAYNE PHARMA GROUP LIMITED
11/23/21